| DC3105 |
BMS-599626 (AC480)
Featured
|
BMS-599626 (AC480) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, respectively. |
|
| DC7730 |
Temsavir（BMS-626529）
Featured
|
BMS-626529 is a novel small-molecule attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T-cells. |
|
| DC9252 |
BMS-687453
Featured
|
BMS687453 is a potent and selective peroxisome proliferator activated receptor (PPAR) α agonist, with an EC50 of 10 nM for human PPARα and ∼410-fold selectivity vs human PPARγ in PPAR-GAL4 transactivation assays. |
|
| DC9700 |
BMS-707035
Featured
|
BMS-707035 is a potent, specific, and reversible HIV-I integrase (IN) inhibitor that blocks HIV IN strand transfer activity. |
|
| DC3114 |
Avagacestat (BMS-708163)
Featured
|
BMS-708163 is a potent, selective γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM, respectively. |
|
| DC3126 |
BMS754807
Featured
|
BMS-754807 is a potent and reversible inhibitor of IGF-1R/IR family kinases, inhibits IGF-1R, IR, Met, TrkA and TrkB with IC50 of 1.8 nM, 1.7 nM, 5.6 nM, 7.4 nM and 4.1 nM, respectively. |
|
| DC9861 |
BMS-779788(XL-652)
Featured
|
BMS-779788(XL652) is a novel small-molecule modulator of the Liver X Receptor (LXR), a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders. |
|
| DC10494 |
BMS813160
Featured
|
BMS-813160 is a dual CCR2/CCR5 chemokine antagonist. |
|
| DC12670 |
BMS-817378 free base
Featured
|
BMS-817378 is a prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833. |
|
| DC20815 |
BMS-823778
Featured
|
BMS-823778 (BMS823778) is an orally available, potent and selective inhibitor of 11βHSD-1 with IC50 of 2.3 nM, displays >10,000-fold selectivity over 11βHSD-2. |
|
| DC7154 |
BMS-833923 (XL-139)
Featured
|
BMS 833923 is an orally bioavailable inhibitor of Smo. It blocks binding of BODIPY cyclopamine (IC50 = 21 nM) and inhibits Gli activation in cell lines that express wild-type Smo or activated mutant forms of Smo (IC50s = 6-35 nM). BMS 833923 robustly inhi |
|
| DC7090 |
BMS-863233 (XL-413)
Featured
|
BMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. |
|
| DC4175 |
BMS-911543
Featured
|
BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, approximately 350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. |
|
| DC23872 |
BMS-932481(BMS932481;BMS 932481)
Featured
|
BMS-932481 (BMS932481) is a potent, selective, orraly active γ-secretase modulator (GSM), shows selectivity for Aβ40 and Aβ42 reduction (IC50=6.6 nM) while sparing total Aβ levels both in vitro and in vivo. |
|
| DC21092 |
BMS-955176
Featured
|
BMS-955176 (GSK-3532795) is a second-generation HIV-1 maturation inhibitor that exhibits potent activity (EC50=3.9±3.4 nM) against a library (n=87) of gag/pr recombinant viruses. |
|
| DC20821 |
BMS-962212
Featured
|
BMS-962212 is a potent, highly selective and reversible small molecule coagulation Factor XIa (FXIa) inhibitor with Ki of 0.7 nM. |
|
| DC10459 |
BMS-986020
Featured
|
BMS-986020 is an LPA1 antagonist. |
|
| DC11923 |
BMS-986120
Featured
|
BMS-986120 (BMS986120) is a potent, selective, orally bioavailable, and reversible PAR4 antagonist with Kd of 0.098 nM for human PAR4. |
|
| DC26073 |
BMS-986122
Featured
|
BMS-986122 is a potent positive allosteric modulator of μ-opioid receptor, significantly increases the inhibition of forskolin-stimulated adenylyl cyclase activity produced by an EC10 (30 pM) concentration of endomorphin-I in CHO-μ cells.. |
|
| DC11819 |
BMS-986142
Featured
|
BMS-986142 is a potent, selective, and reversible BTK (Bruton’s tyrosine kinase) inhibitor (BTK IC₅₀ = 0.5nM; human WB IC₅₀ = 90 nM). |
|
| DC10609 |
BMS-986158
Featured
|
BMS-986158 is an inhibitor of the bromodomain and extra-terminal (BET) proteins. |
|
| DC12174 |
Deucravacitinib(BMS986165)
Featured
|
BMS-986165 is a selective, potent, allosteric inhibitor of tyrosine kinase 2 (Tyk2). |
|
| DC23532 |
BMS-986166
Featured
|
BMS-986166 (BMS986166) is a potent, selective S1P receptor modulator for the treatment of ulcerative colitis.. |
|
| DC23460 |
BMS986187
Featured
|
BMS-986187 is a novel potent, positive allosteric modulator of δ-opioid receptor with EC50 of 30 nM, 100-fold selectivity over μ-opioid receptor.. |
|
| DC12030 |
BMS-986195
Featured
|
BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). |
|
| DC10924 |
BMS986202
Featured
|
BMS-986202 is a clinical Tyk2 inhibitor that binds to Tyk2 JH2 with IC50 of 0.19 nM and shows remarkably selectivity over other kinases including Jak family members. |
|
| DC10131 |
BMS-986205(Linrodostat)
Featured
|
BMS-986205 is an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic activity, alone and in combination with nivolumab in advanced cancers in a phase 1/2a trial |
|
| DC23998 |
BMX-IN-1
Featured
|
BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity. |
|
| DC7377 |
BMY 7378
Featured
|
BMY 7378 is a multi-targeted inhibitor of α2C-adrenoceptor and α1D-adrenoceptor with pKi of 6.54 and 8.2, respectively, and acts as a mixed agonist and antagonist for 5-HT1A receptor with pKi of 8.3. |
|
| DC7773 |
BNC-105
Featured
|
BNC105 is a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. |
|
